147 related articles for article (PubMed ID: 36073307)
1. A case of cytokine release syndrome accompanied with COVID-19 infection during treatment with immune checkpoint inhibitors for non-small cell lung cancer.
Murata D; Azuma K; Tokisawa S; Tokito T; Hoshino T
Thorac Cancer; 2022 Oct; 13(20):2911-2914. PubMed ID: 36073307
[TBL] [Abstract][Full Text] [Related]
2. Cytokine release syndrome complicated with severe rashes induced by nivolumab plus ipilimumab therapy in a patient with non-small cell lung cancer: A case report.
Tsutsui T; Hata K; Kawaguchi M; Kobayashi H; Kakizaki Y; Miyashita Y
Thorac Cancer; 2023 Aug; 14(23):2310-2313. PubMed ID: 37381088
[TBL] [Abstract][Full Text] [Related]
3. Severe Cytokine Release Syndrome and Immune Effector Cell-associated Neurotoxicity Syndrome in a Man Receiving Immune Checkpoint Inhibitors for Lung Cancer.
Tanaka T; Taoka M; Makimoto G; Ninomiya K; Higo H; Fujii M; Ichihara E; Ohashi K; Hotta K; Tabata M; Maeda Y
Intern Med; 2024 May; 63(9):1261-1267. PubMed ID: 37722894
[TBL] [Abstract][Full Text] [Related]
4. Five Cases of Cytokine Release Syndrome in Patients Receiving Cytotoxic Chemotherapy Together With Nivolumab Plus Ipilimumab: A Case Report.
Shiraishi Y; Tokito T; Toyozawa R; Inagaki C; Nokihara H; Kawashima Y; Ohe Y; Okamoto I
J Thorac Oncol; 2024 Feb; 19(2):337-343. PubMed ID: 37943237
[TBL] [Abstract][Full Text] [Related]
5. Nivolumab-Induced Cytokine Release Syndrome: A Case Report and Literature Review.
Ntwali F; Gilliaux Q; Honoré PM
Am J Case Rep; 2024 Apr; 25():e941835. PubMed ID: 38625840
[TBL] [Abstract][Full Text] [Related]
6. Perimyocarditis Associated with Immune Checkpoint Inhibitors: A Case Report and Review of the Literature.
Shalata W; Steckbeck R; Abu Salman A; Abu Saleh O; Abu Jama A; Attal ZG; Shalata S; Alnsasra H; Yakobson A
Medicina (Kaunas); 2024 Jan; 60(2):. PubMed ID: 38399513
[TBL] [Abstract][Full Text] [Related]
7. Cytokine release syndrome in a patient with non-small cell lung cancer on ipilimumab and nivolumab maintenance therapy after vaccination with the mRNA-1273 vaccine: a case report.
Sumi T; Koshino Y; Michimata H; Nagayama D; Watanabe H; Yamada Y; Chiba H
Transl Lung Cancer Res; 2022 Sep; 11(9):1973-1976. PubMed ID: 36248324
[TBL] [Abstract][Full Text] [Related]
8. Severe cytokine release syndrome resulting in purpura fulminans despite successful response to nivolumab therapy in a patient with pleomorphic carcinoma of the lung: a case report.
Honjo O; Kubo T; Sugaya F; Nishizaka T; Kato K; Hirohashi Y; Takahashi H; Torigoe T
J Immunother Cancer; 2019 Apr; 7(1):97. PubMed ID: 30944043
[TBL] [Abstract][Full Text] [Related]
9. A case report of fulminant cytokine release syndrome complicated by dermatomyositis after the combination therapy with immune checkpoint inhibitors.
Ohira J; Kawamoto M; Sugino Y; Kohara N
Medicine (Baltimore); 2020 Apr; 99(15):e19741. PubMed ID: 32282733
[TBL] [Abstract][Full Text] [Related]
10. [Ipilimumab-nivolumab as first-line treatment in metastatic NSCLC].
El-Ghazzi N; Lavaud P
Bull Cancer; 2021 Mar; 108(3):231-233. PubMed ID: 33622569
[No Abstract] [Full Text] [Related]
11. Nivolumab plus ipilimumab for the first-line treatment of metastatic NSCLC.
Rijavec E; Indini A; Ghidini M; Tomasello G; Cattaneo M; Barbin F; Grossi F
Expert Rev Anticancer Ther; 2021 Jul; 21(7):705-713. PubMed ID: 33719827
[TBL] [Abstract][Full Text] [Related]
12. Case Report: Clinical Management of a Patient With Metastatic Non-Small Cell Lung Cancer Newly Receiving Immune Checkpoint Inhibition During Symptomatic COVID-19.
Mellinghoff SC; Vanshylla K; Dahlke C; Addo MM; Cornely OA; Klein F; Persigehl T; Rybniker J; Gruell H; Bröckelmann PJ
Front Immunol; 2021; 12():798276. PubMed ID: 34987520
[TBL] [Abstract][Full Text] [Related]
13. Delayed cytokine release syndrome after neoadjuvant nivolumab: a case report and literature review.
Ciner AT; Hochster HS; August DA; Carpizo DR; Spencer KR
Immunotherapy; 2021 Sep; 13(13):1071-1078. PubMed ID: 34287029
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of Nivolumab-Ipilimumab Combination Therapy for the Treatment of Advanced Non-Small Cell Lung Cancer.
Courtney PT; Yip AT; Cherry DR; Salans MA; Kumar A; Murphy JD
JAMA Netw Open; 2021 May; 4(5):e218787. PubMed ID: 33938936
[TBL] [Abstract][Full Text] [Related]
15. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
16. Unusual skin toxicity associated with sustained disease response induced by nivolumab in a patient with non-small cell lung cancer.
Galli G; Proto C; Cossa M; Valeri B; Sdao S; Signorelli D; Imbimbo M; de Braud F; Garassino MC; Lo Russo G
Tumori; 2019 Dec; 105(6):NP57-NP62. PubMed ID: 31456503
[TBL] [Abstract][Full Text] [Related]
17. Cytokine Release Syndrome Induced by Immune-checkpoint Inhibitor Therapy for Non-small-cell Lung Cancer.
Yomota M; Mirokuji K; Sakaguchi M; Kitahara Y; Chin F; Setoguchi K; Hosomi Y
Intern Med; 2021 Nov; 60(21):3459-3462. PubMed ID: 33775995
[TBL] [Abstract][Full Text] [Related]
18. Hemophagocytic lymphohistiocytosis induced by nivolumab/ipilimumab combination therapy: A case of lung adenocarcinoma that responded to early steroid pulse therapy.
Hagiwara S; Tanizaki J; Hayashi H; Komeda Y; Nishida N; Yoshida A; Yamamoto T; Matsubara T; Kudo M
Cancer Rep (Hoboken); 2024 Feb; 7(2):e1960. PubMed ID: 38196303
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer.
Reuss JE; Anagnostou V; Cottrell TR; Smith KN; Verde F; Zahurak M; Lanis M; Murray JC; Chan HY; McCarthy C; Wang D; White JR; Yang S; Battafarano R; Broderick S; Bush E; Brock M; Ha J; Jones D; Merghoub T; Taube J; Velculescu VE; Rosner G; Illei P; Pardoll DM; Topalian S; Naidoo J; Levy B; Hellmann M; Brahmer JR; Chaft JE; Forde PM
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32929052
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and safety of immune checkpoint inhibitors: A retrospective study in Taiwan.
Hsu JC; Lin JY; Hsu MY; Lin PC
PLoS One; 2018; 13(8):e0202725. PubMed ID: 30142174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
